Claris Ventures
Investor profile
Venture capital
Claris Ventures has backed 5 European tech companies across 6 funding rounds between 2022 and 2024, joining rounds totalling €70M. Most active in Healthtech. Data as of Nov 2026.
Deals
6
distinct rounds
Companies
5
backed
Active span
2022–2024
3 yrs
Total round €
€70M
sum of rounds joined
Deals by year
distinct rounds / yearClaris Ventures — deals by year — interactive chart.
Data table
| Claris Ventures — deals by year | |
|---|---|
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 1 |
Top sectors
by dealsClaris Ventures — top sectors — interactive chart.
Data table
| Claris Ventures — top sectors | |
|---|---|
| Healthtech | 6 |
Stages
by dealsClaris Ventures — stages — interactive chart.
Data table
| Claris Ventures — stages | |
|---|---|
| Seed | 2 |
| Series A | 2 |
| Series B | 2 |
Countries
by dealsClaris Ventures — countries — interactive chart.
Data table
| Claris Ventures — countries | |
|---|---|
| Italy | 5 |
| UK | 1 |
Co-investment network
shared roundsCo-investment network — interactive chart.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
Frequent co-investors
shared rounds- 3B Future Health Fund3
- 2Invest2
- CDP Venture Capital2
- Italian Angels for Growth2
- ACE & Company1
- Alef 61
- Astellas Venture Management1
- Club degli Investitori1
- CRT Pioneer Fund1
- Ersel1
- Evolution Ventures1
- Indaco Venture Partners1
- Pietro Puglisi1
- Seroba Life Sciences1
- Sunstone Life Science Ventures1
- V-Bio Ventures1
- Vertis SGR1
- VI Partners1
Portfolio
top 30 by total round €| Company | Country | Rounds | Total € |
|---|---|---|---|
| Sibylla Biotech | Italy | 1 | €23M |
| Resalis Therapeutics | Italy | 2 | €20M |
| Kither Biotech | Italy | 1 | €19M |
| NeoPhore | UK | 1 | €6.8M |
| Repron Therapeutics | Italy | 1 | €2.0M |
Biggest deals
top 10 by amount| Company | Stage | Amount | Date |
|---|---|---|---|
| Sibylla Biotech | Series A | €23M | 2022-10 |
| Kither Biotech | Series B | €19M | 2022-03 |
| Resalis Therapeutics | Series A | €10M | 2024-01 |
| Resalis Therapeutics | Seed | €10M | 2023-02 |
| NeoPhore | Series B | €6.8M | 2023-01 |
| Repron Therapeutics | Seed | €2.0M | 2023-06 |